Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 27 of 27 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/29/24
End: 03/31/28
Due: 03/31/29
Phase: N/A
Priority: Normal
Start: 04/12/21
End: 05/05/22
Due: 05/05/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) | NCT06539182 | Dizal Pharmaceuticals | user2@example.com | None | 2024-04-29 | 2028-03-31 | 2029-03-31 | - | - | 2025-07-14 |
| Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | NCT04634344 | Dizal Pharmaceuticals | user2@example.com | None | 2021-04-12 | 2022-05-05 | 2023-05-05 | - | - | 2025-07-14 |